Clinical Trial Update: NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy [Phase 2]

View source ↗

Summary

Phase 2 trial from MD Anderson evaluating psilocybin to prevent chemotherapy-induced peripheral neuropathy; currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Peripheral Neuropathy

Drugs mentioned

• Psilocybin (psilocybin)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Psilocybin, Neuropathy | Phase 2 | Status: NOT_YET_RECRUITING